Fig. 1: Schematic of entire clinical CAR-T cohort treated at DFCI from 2017 to 2023.
From: A clonally expanded nodal T-cell population diagnosed as T-cell lymphoma after CAR-T therapy
583 patients did not develop secondary malignancy after CAR-T (gray box). Left pie chart—breakdown of primary disease of these 583 patients. Right pie chart—breakdown of CAR-T product received by these 583 patients. Red box—43 patients developed secondary malignancy after CAR-T, with 3 TCL cases, 12 myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), 28 solid tumor. Colors indicate CAR-T product each patient received.
